May 11,2022

COPD Rehabilitation App Improves At-Home Outcomes Following Inpatient Rehabilitation

In the study conducted by physicians at Zurich Rehabilitation Centers in Switzerland and the University of Marburg in Germany patients were tracked for 6 months following their release from rehabilitation. Half of the 60 patients were asked to use Kaia Health’s COPD app to assist their rehabilitation. The data showed patients who used the app had increased physical activity compared to the control group. It also showed that app users had improved scores on the COPD Assessment Test, in which patients rate symptoms such as coughing, congestion, and chest tightness.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 23,2022

Swiss multicentre study to investigate the effect of ePRO-based model of care on early detection and management of immune-related adverse events

Kaiku Health is taking part in a study assessing the use of an electronic Patient-Reported Outcome (ePRO)-based model of care to evaluate onset of symptomatic immune-related adverse events in cancer patients and their detection by healthcare providers. This phase-II randomised controlled trial, comparing the ePRO-based model of care to the current standard model of care, is conducted at the Geneva University Hospitals and Lausanne University Hospital, Switzerland.

CLINICAL STUDY

#rpm

View Analyst & Ambassador Comments
Go to original news
May 24,2022

PEAR ANNOUNCES HEALTH EQUITY DATA SHOWING SIMILAR ENGAGEMENT WITH RESET-O® ACROSS US GEOGRAPHIC REGIONS PRESENTED AT APA ANNUAL MEETING

Pear Therapeutics, the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced study data that found similar engagement with reSET-O®, the only FDA-authorized PDT for the treatment of opioid use disorder (OUD), among patients across a broad range of US geographic regions, including urban and rural. The study assessed a database of de-identified data from 5,263 patients with OUD who completed at least one lesson in a 12-week course of treatment with reSET-O to determine levels of engagement across geographic subgroups.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 27,2022

Study: VR therapeutic reduces pain intensity long term, compared with sham app

The study was sponsored by AppliedVR and used its RelieVRx system, formerly known as EaseVRx, to assess its long-term effectiveness for people with chronic lower-back pain (CLBP). It followed up on earlier research that analyzed the immersive eight-week program, compared with a 2D sham experience immediately after treatment. Meanwhile, 38% of the RelieVRx cohort achieved substantial clinical meaningfulness, while only 13.2% of the sham group did.

CLINICAL STUDY

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Jun 03,2022

DarioHealth Presents Three New Studies Demonstrating Improved Health in Users with Multiple Conditions at the American Diabetes Association's 82nd Scientific Sessions

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today three new research studies presented at the American Diabetes Association's ("ADA") 82nd Scientific Sessions being held June 3rd to 7th, 2022 in New Orleans, Louisiana.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 04,2022

One Drop Study Signals Significant Growing Interest in Continuous Glucose Monitors (CGMs) Among People with Type 2 Diabetes

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, presented new research at the 82nd Scientific Sessions of the American Diabetes Association on attitudes and adoption of continuous glucose monitors (CGM) among people with type 2 diabetes (T2D).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 04,2022

One Drop’s Digital Solution Helps People with Type 2 Diabetes Who Are at Greater Risk of Health Inequities

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, presented new research at the 82nd Scientific Sessions of the American Diabetes Association (ADA 2022) linking cumulative risk of health inequities to platform engagement and attitudes towards One Drop among people with type 2 diabetes.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 06,2022

ieso Announces Results Showing Novel Form of Online Cognitive Behavioral Therapy Improves Patient Outcomes in Type 2 Diabetes

ieso, a data-driven AI healthcare company pioneering next-generation digital therapeutics in mental health, announced today study results showing that integrated approaches for mental healthcare in diabetes patients improved mental health outcomes, patient engagement with self-management of diabetes, diabetes distress, and quality of life. This study, conducted with support from Roche Diabetes Care Limited, enrolled 102 patients and evaluated the effect of a novel online CBT tailored for patients with type 2 diabetes.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Jun 06,2022

Pear Presents Interim Real-World Data Showing Significant Reductions In Symptoms Of Chronic Insomnia, Anxiety And Depression With Somryst® At Sleep 2022

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced interim follow-up real-world data from DREAM, a remote, decentralized trial, that showed treatment with Somryst®, the only FDA-authorized PDT for the treatment of chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity both immediately following treatment and six months later. Interim data from the DREAM study (NCT04325464), a remote, virtual, open-label, decentralized clinical trial evaluating Somryst, analyzed in mid-Q1 2022, included 993 adult patients (22-75 years of age) enrolled to date with chronic insomnia living in the U.S. who had access to a mobile device. As part of its PearCreate™ platform, Pear has developed its own remote, decentralized, virtual clinical trial infrastructure for participant recruitment, screening, consent, enrollment, follow up, and progress tracking, which was used for the DREAM study.

CLINICAL STUDY

#pdt

#rwe

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 06,2022

Pear Therapeutics Announces New Analysis Showing Reduction In Healthcare Resource Utilization And Associated Costs In Patients Using Reset® At Six Months

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced a manuscript accepted for publication and available via pre-print of a real-world study demonstrating reduced resource utilization and associated costs for reSET®, the only FDA-authorized PDT for the treatment of substance use disorder (SUD), including alcohol, cannabis, cocaine, and stimulants.

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY